Vonoprazan-d₃ fumarate 

Vonoprazan-d₃ fumarate is the deuterium labeled Vonoprazan fumarate (HY-15295). Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease^[1][2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[75].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

464.48

C₂₁H₁₇D₃FN₃O₆S

1260141-27-2

OC(/C=C/C(O)=O)=O.O=S(N1C(C2=C(C=CC=C2)F)=CC(CNC([2H])([2H])[2H])=C1)(C3=CN=CC=C3)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.  [Content Brief]